Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirtris Pharmaceuticals has signed a license agreement with the Massachusetts Institute of Technology for intellectual property related to SIRT1 as a novel mechanism that affects atherosclerosis and other age-related diseases.
Subscribe to our email newsletter
This agreement provides Sirtris with exclusive rights to intellectual property covered under the patent ‘cholesterol-regulating complex of SIRT1 and LXR and methods of use.’
Karl Normington, Sirtris’ senior director of intellectual property, said: “Sirtuins are attractive drug targets which may be therapeutically beneficial for metabolic, neurological, and cardiovascular diseases. This license further strengthens Sirtris’ intellectual property estate for drugs that may address diseases of aging.”